Últimas noticias sobre ARK Genomic Revolution ETF (BATS:ARKG)

ARK Genomic Revolution Multi-Sector ETF

Healthcare

Other

Technology

Financial Services

The Fund is an actively managed exchange-traded fund (ETF) that will invest under normal circumstances primarily (at least 80 percent of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the Funds investment theme of the genomics* revolution (Genomics Revolution Companies). Under normal circumstances, substantially all of the Funds assets will be invested in equity securities, including common stocks, partnership interests, business trust shares and other equity investments or ownership interests in business enterprises. The Funds investments will include micro-, small-, medium- and large-capitalization companies. The Funds investments in foreign equity securities will be in both developed and emerging markets.

Twist Bioscience Corp.

Caredx

Crispr Therapeutics Ag

Recursion Pharmaceuticals, Inc.

Ionis Pharmaceuticals Inc

Intellia Therapeutics

Beam Therapeutics Inc

Schrodinger, Inc.

Adaptive Biotechnologies Corporation

10X Genomics Inc

ARK Genomic Revolution ETF

Equities

News

Markets

ARKG

ARKK

Ejecutivos de Tempus AI vendieron acciones por 20,3M$ tras el impresionante repunte del valor. ¿Qué implica esto para la empresa?

¿Por qué los ejecutivos de Tempus AI (TEM) vendieron acciones tras su increíble subida?

ABSI

ACCD

ARKQ

ARKX

ESLT

ILMN

NTLA

OKLO

PATH

Descubre las recientes decisiones de Ark Invest en energía, defensa y genética, con transacciones millonarias en empresas clave.

Ark Invest adquiere y vende acciones clave en energía, defensa y tecnología genética

Tech

ETFs

ADPT

CDNA

PLTR

VCYT

Ark Invest sorprende con grandes movimientos en Palantir y Tempus AI. Descubre el impacto de estas decisiones clave.

Cathie Wood apuesta 12,2M$ en Tempus AI (TEM) mientras reduce exposición a Palantir (PLTR)

Outlook
For 2025, management expects revenue between $390 million and $430 million, inclusive of contributions from the E2E acquisition. Management expects Non-GAAP operating margins to be at least 10% at the low end of this revenue range, with improved free cash flow compared to 2024.

CRNT

Ceragon 2025 Forecast: Revenue To be $390M–$430M Vs. $415.2M Est.; Margins Expected At 10% Minimum

Ethereum&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance compared to other big cryptocurrencies has caused a stir in the crypto community, but its leadership maintains that its culture is the key <a href="https://www.benzinga.com/money/ethereum-eth-price-predictions">to long-term success.</a>
What Happened: According to Devansh Mehta, public goods and governance lead at the Ethereum Foundation, Ethereum&#8217;s strong, community-driven culture focused on openness, transparency and challenging authority is Ethereum&#8217;s core strength.
In an interview with Benzinga, Mehta said this unique culture attracts top-tier talent and fosters innovation, giving Ethereum a significant advantage over competitors.
Mehta emphasized that Ethereum&#8217;s strength lies not just in its technology, but in the collective values of its contributors. 
&#8220;Ethereum wins because of its community,&#8221; Mehta stated, highlighting the presence of &#8220;top notch teams all working in the same ecosystem, sharing similar values of openness, transparency and rebelliousness against authority.&#8221;
He contrasted Ethereum&#8217;s culture with that of other blockchain projects, stating, &#8220;Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) doesn&#8217;t have that &#8211; a lot of their code and wallets cant be verified by anyone. XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) isn&#8217;t so much for the rebels &#8211; its value prop is working with governments.&#8221; 
Mehta believes that the &#8220;mavericks and the rebels&#8221; are the driving force behind shareholder value creation in the 21st century.
Mehta urged Ethereum investors to focus on the quality and values of the individuals within the Ethereum ecosystem, rather than solely focusing on price fluctuations. 
&#8220;My message to ETH investors would be to look past the immediate price and instead search for intangibles like: what is the quality of people in the EVM ecosystem? Are the people working in the Ethereum universe people that i would bet on? How supportive is Ethereum of its best builders?&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43605114/dave-portnoy-holds-millions-in-bitcoin-and-xrp-but-heres-why-he-concluded-his-heart-is-too-big-for-this-space">Dave Portnoy Holds Millions In Bitcoin And XRP, But Here&#8217;s Why He Concluded His Heart Is &#8216;Too Big For This Space&#8217;</a>
Why It Matters: Mehta has been recently appointed to the top post amid recent events have cast a shadow on this Ethereum&#8217;s narrative.
Leadership struggles and investor concerns regarding Ethereum&#8217;s long-term viability have prompted Ethereum creator Vitalik Buterin to assert his control over the Foundation&#8217;s future direction. 
Buterin took to social media to <a href="https://x.com/VitalikButerin/status/1881680518934384676">emphasize</a> that he will personally oversee any upcoming leadership changes, while ensuring that his decisions are not influenced by outside pressure.
The increased pressure from investors stems from growing unease about the perceived inaction of the Ethereum Foundation amid declining market legitimacy. 
This internal discord has even led to the departure of veteran developer Eric Conner, who <a href="https://x.com/econoar/status/1881554156261122535">expressed </a>frustration with the leadership&#8217;s disconnect from the community&#8217;s needs and values. 
Conner stated his hope that leadership might eventually realign with the community, but felt compelled to step away for now.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43600376/netvrk-launches-silkai-aims-to-deliver-hyperintelligent-ai-agents-to-metaverse">NetVRk Launches SilkAI, Aims To Deliver Hyperintelligent AI Agents To Metaverse</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$SOL

$XRP

Ethereum Has A Key Strength That XRP, Solana Don't Have, Expert Says

2025 Business Outlook
<ul>
<li>Full-year 2025 Adjusted EBITDA(1)(3) to be in a range of $1.90 billion to $1.95 billion</li>
<li>Total operating expenses(4) to be in a range of $900 million to $925 million</li>
<li>Growth capital expenditures of at least $400 million</li>
<li>Maintenance capital expenditures of approximately $150 million</li>
</ul>

Guidance

Sunoco Sees FY25 Adjusted EBITDA $1.90B-$1.95B, Growth Capex Of At least $400M

Biotech

Large Cap

Health Care

General

Health Canada Has Approved Merck's Keytruda (Pembrolizumab) For Adult Patients With Resectable Stage II, IIIA, or IIIB (T3-4N2) Non-Small Cell Lung Carcinoma In Combination With Platinum-Containing Chemotherapy As Neoadjuvant Treatment, And Then Continued As Monotherapy As Adjuvant Treatment After Surgery

VYGR

Voyager Therapeutics Announced It Has Decided To Assess Alternate Payloads Related To Its Gene Therapy Program For Superoxide Dismutase 1 (SOD1) Amyotrophic Lateral Sclerosis (ALS)

<h3>Gainers</h3>
<ul>
<li>BJ's Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) stock increased by 24.2% to $43.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.0 billion. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares rose 20.27% to $0.13. The market value of their outstanding shares is at $35.1 million. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares moved upwards by 16.99% to $1.79. The market value of their outstanding shares is at $2.4 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock moved upwards by 11.41% to $2.05. The company's market cap stands at $23.5 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares rose 10.76% to $3.6. The company's market cap stands at $32.5 million. </li>
<li>Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) stock rose 8.88% to $18.99. The market value of their outstanding shares is at $597.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MGO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares decreased by 25.1% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $4.8 million. </li>
<li>PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) shares declined by 21.45% to $4.14. The market value of their outstanding shares is at $85.5 million. The company's, Q3 earnings came out yesterday. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) shares declined by 12.29% to $2.0. The market value of their outstanding shares is at $70.2 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares decreased by 9.18% to $0.49. The company's market cap stands at $10.7 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares fell 7.24% to $0.29. The market value of their outstanding shares is at $4.6 million. </li>
<li>Youdao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) shares fell 7.21% to $10.3. The company's market cap stands at $1.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJRI

CLEU

HOUR

JZXN

LINC

MGOL

PETS

SPHL

TRNR

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 64.9% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock moved upwards by 50.47% to $0.22. The market value of their outstanding shares is at $7.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 20.21% to $5.59. The market value of their outstanding shares is at $251.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock increased by 15.78% to $2.64. The company's market cap stands at $5.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares increased by 15.26% to $1.51. The market value of their outstanding shares is at $6.0 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 10.53% to $0.11. The company's market cap stands at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares fell 17.4% to $0.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $49.5 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) shares declined by 11.3% to $9.11. The market value of their outstanding shares is at $482.5 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 10.75% to $0.61. The market value of their outstanding shares is at $21.5 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 10.62% to $4.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares fell 9.56% to $1.42. The market value of their outstanding shares is at $169.8 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 9.0% to $0.44. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVGR

BDRX

CNSP

DHAI

IVVD

LIPO

LIXT

OCEA

PRLD

SLXN

STOK

THRD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy. The target action date for the FDA decision is July 10, 2025.
Acceptance of the BLA resubmission follows the resolution of third-party fill/finish manufacturing issues, which was the sole approvability issue identified by the FDA in the previous submission. The BLA is supported by data from the pivotal <a href="https://www.globenewswire.com/Tracker?data=032VzgfH3Zwknll4UBWp8zhL6nLWeVfQ1uAUbAV9jnbajCy8FTsCvmUFAcFkm2eV2t8IsNs_EENj37PPYz-UlBqu0UDpGan2Fb0QI2pnGVLOoY0TTAijCF94frYMM2vmpGyaZQXMcarXAK7CoIb_u_KN_JrMo6DgxNNL8nroMNCP8WxgVYfRst4Y4E16DQxgOhjw4zyPn14Rb0E4YfjvaA==">LINKER-MM1</a> trial investigating linvoseltamab in R/R MM, and linvoseltamab is also under <a href="https://www.globenewswire.com/Tracker?data=VbdWV_4JC1drSn1toq6OXZrfe0cN2O7_-1sX29HBZEhwCraOE4NHWui62si87wvGd_evR2y4lyNT3suHRjq5Unu5_dIpapz8ZNlk4DAEdaql_zXgO3uLdRsY7W_5_Qh1i4ibQb8-BPGiH7K1yDxOsY3Mq-p-i3oU-iiMXVErUzjEtQlvuxgmzOjmgqrPDBM6FoGMQDUJhRnDgmdZPq7OZw==">review</a> by the&nbsp;European Medicines Agency (EMA) for the same patient population.
Linvoseltamab is investigational and has not been approved by any regulatory authority.

Government

Regulations

REGN

Regeneron Clears Manufacturing Hurdle as FDA Sets July 2025 Decision Date for Linvoseltamab in Multiple Myeloma

<h3>Gainers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares moved upwards by 46.4% to $1.01 during Tuesday's pre-market session. The market value of their outstanding shares is at $30.2 million. </li>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares moved upwards by 17.64% to $3.8. The company's market cap stands at $28.7 million. </li>
<li>Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) shares rose 16.85% to $34.74. The company's market cap stands at $914.2 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock moved upwards by 8.08% to $1.07. The company's market cap stands at $53.5 million. </li>
<li>Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) stock increased by 7.76% to $4.86. The company's market cap stands at $465.5 million. </li>
<li>Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) stock moved upwards by 6.51% to $22.89. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares declined by 38.0% to $8.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) shares declined by 21.49% to $1.06. The market value of their outstanding shares is at $22.7 million. </li>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) stock fell 10.42% to $4.0. The company's market cap stands at $11.1 million. </li>
<li>Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) shares declined by 8.55% to $32.45. The company's market cap stands at $930.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) stock decreased by 7.0% to $1.33. The company's market cap stands at $17.9 million. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) shares fell 6.85% to $0.9. The market value of their outstanding shares is at $20.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMCO

ELPW

FBGL

FLNC

MNTS

NCEW

RAIN

SATL

SFHG

VSTE

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares moved upwards by 38.4% to $0.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.4 million. </li>
<li>Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) stock rose 14.3% to $62.26. The company's market cap stands at $8.5 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) shares moved upwards by 10.04% to $0.54. The market value of their outstanding shares is at $4.5 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock rose 9.35% to $0.29. The company's market cap stands at $7.4 million. </li>
<li>Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) shares rose 7.98% to $2.3. The company's market cap stands at $234.2 million. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) shares rose 7.34% to $1.9. The company's market cap stands at $38.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) shares decreased by 27.4% to $8.07 during Tuesday's pre-market session. The company's market cap stands at $940.3 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock declined by 18.72% to $0.56. The company's market cap stands at $21.4 million. </li>
<li>Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) shares decreased by 16.84% to $9.29. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) shares declined by 13.48% to $1.22. The company's market cap stands at $9.2 million. </li>
<li>Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) stock fell 9.49% to $22.05. The market value of their outstanding shares is at $5.4 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock decreased by 8.68% to $11.27. The company's market cap stands at $164.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

BNAI

BTOG

CSAI

HLIT

LSCC

PERF

SCKT

VRAR

VSAT

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Third Harmonic Bio Says THB335 Phase 1 Data Supports Advancement Into Phase 2 Clinical Trial In Chronic Spontaneous Urticaria (CSU)

Distribution
On January 27, 2025, the Board of Directors of SUN's general partner declared a distribution for the fourth quarter of 2024 of $0.8865 per unit, or $3.5460 per unit on an annualized basis. The distribution will be paid on February 19, 2025, to common unitholders of record on February 7, 2025.
The Partnership is targeting a distribution growth rate of at least 5% for 2025 and will announce future increases quarterly.

Dividends

Sunoco Targets Distribution Growth Rate Of At Least 5% For 2025 And Will Announce Future Increases Quarterly

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

Reiteration

Analyst Ratings

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Masco Sees FY25 Adj. EPS Of $4.20 - $4.45 Vs. $4.40 Est.

<ul>
<li>Revenue to grow at a mid-twenties percentage rate on a year-over-year basis;</li>
<li>Gross profit dollars to grow at a low-twenties percentage rate on a year-over-year basis;</li>
<li>Operating expense as a percentage of revenue to be 41% to 42%;</li>
<li>Stock-based compensation to be $120 million; and</li>
<li>Free cash flow margin to be in the mid-teens.</li>
</ul>

SHOP

Shopify Sees Q1 2025 Revenue Growth Mid-Twenties Percentage Rate On YoY Basis

Subject to the finalization of financial reporting processes, including the finalization of income taxes, net income for the fourth quarter of 2024 is expected to be between $31 million and $37 million, compared to a net loss of $12 million in the fourth quarter of 2023.
 &nbsp;

PSFE

Paysafe Expects Q4 Revenue To Be $420M (Est $437.54M), Up 1% YoY, Or 4% When Excluding The Disposed Business

Earnings

ARVN

Arvinas Says Its Cash, Cash Equivalents, And Marketable Securities Of $1.04B As Of December 31, 2024, Is Sufficient To Fund Planned Operating Expenses And Capital Expenditure Requirements Into 2027

WIIM

Marriott shares are trading lower following soft Q1 guidance.

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="4">Summary of First Quarter 2025 Guidance (Unaudited, in millions, except per share amounts)(1)</td>
</tr>
<tr>
<td>IFRS</td>
<td>Share-based compensation</td>
<td>Non-IFRS (2)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net revenue</td>
<td>$1,550 - $1,600</td>
<td>&nbsp;</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Gross profit</td>
<td>$325 - $370</td>
<td>$14 - $16</td>
<td>$341 - $384</td>
</tr>
<tr>
<td>Gross margin(3) (mid-point)</td>
<td>22.1%</td>
<td>23.0%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Operating profit</td>
<td>$94 - $167</td>
<td>$47 - $57</td>
<td>$151 - $214</td>
</tr>
<tr>
<td>Operating margin(3) (mid-point)</td>
<td>8.3%</td>
<td>11.6%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Net income (4)</td>
<td>$78 - $142</td>
<td>$47 - $57</td>
<td>$135 - $189</td>
</tr>
<tr>
<td>Net income margin(3) (mid-point)</td>
<td>7.0%</td>
<td>10.3%</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>Diluted EPS</td>
<td>$0.14 - $0.26</td>
<td>$0.24 - $0.34</td>
<td>&nbsp;</td>
</tr>
</tbody>
</table>
</figure>

GlobalFoundries Expects Q1 Revenue Of $1.55B-$1.60B Vs $1.66B Est, Adj EPS Of $0.24-$0.34 Vs $0.32 Est

Marriott Sees Q1 Adj. EPS $2.20-$2.26 vs $2.37 Est., RevPAR Growth 3%-4%; Sees FY25 Adj. EPS $9.82-$10.19 vs $10.65 Est., RevPAR Growth 2%-4%

Cathie Wood's Ark Invest has significantly increased its stake in Tempus AI ($TEM) by acquiring over 600,000 shares across its funds since the star...

Cathie Wood Boosts Stake in Tempus AI (TEM) and Avoids Trump Coin

ARKG: Eyeing Favorable Macro 2025 Turns, Encouraging Momentum Trends

Tech-Enabled Health: Revolutionizing The Standard Of Care

From Underperformance To Opportunity: Biotech's Case For 2025

Under-The-Radar Opportunities In ETFs

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.

Comments

ARK Genomic Revolution ETF

Noticias

Últimas noticias sobre ARK Genomic Revolution ETF (BATS:ARKG)

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL